BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas



Status:Recruiting
Conditions:Brain Cancer, Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:13 - 25
Updated:4/6/2019
Start Date:April 3, 2019
End Date:July 2027
Contact:Kelly Hitchner
Email:PNOC_Regulatory@ucsf.edu
Phone:415-502-1600

Use our guide to learn which trials are right for you!

A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas

This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in
treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly
diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may
work better in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma.

PRIMARY OBJECTIVES:

I. Determine the safety and tolerability of the combination of Poly (ADP-Ribose) polymerase
(PARP) inhibitor BGB-290 (BGB-290) and temozolomide (TMZ) in adolescent and young adult (AYA)
subjects with IDH1/2-mutant glioma, including the maximum tolerated dose (MTD) and
characterization of dose-limiting toxicities (DLTs) in both, newly diagnosed and recurrent
treatment arms.

EXPLORATORY OBJECTIVES:

I. Evaluate the preliminary efficacy of BGB-290 and temozolomide in terms of progression free
survival (PFS) and overall survival (OS) in Arm A and B stratified by tumor diagnosis,
calculated using the Kaplan-Meier method with a goal of improving the historical high grade
glioma progression free survival of 10% and overall survival of 20% at 2 years.

II. Assess the mutational landscape studies via whole-exome sequencing (WES). III. Assessment
of gene expression patterns using ribonucleic acid (RNA) sequencing (RNAseq).

IV. Assess the methylation profiling with Infinium methylation assays. V. Assess the
oncometabolite profiling via liquid chromatography (LC)/mass spectrometry (MS)-MS.

VI. Assess the intratumoral drug level assessments via LC/MS-MS.

OUTLINE: This is a dose-escalation study. Patients are assigned to 1 of 2 cohorts. After the
MTD is established, additional patients will be enrolled into the efficacy component of the
trial.

ARM A: Newly diagnosed IDH1/2-mutant high-grade glioma patients receive PARP inhibitor
BGB-290 orally (PO) twice daily (BID) on days 1-28 and temozolomide PO daily on days 1-21.
Courses repeat every 28 days for up to 24 months in the absence of disease progression or
unacceptable toxicity.

ARM B: Recurrent IDH1/2-mutant low-grade or high-grade glioma patients receive PARP inhibitor
BGB-290 orally (PO) twice daily (BID) on days 1-28 and temozolomide PO daily on days 1-21.
Courses repeat every 28 days for up to 24 months in the absence of disease progression or
unacceptable toxicity.

COHORT B0: Recurrent IDH1/2-mutant low-grade or high-grade glioma patients receive PARP
inhibitor BGB-290 PO for 7 days pre-surgery at the MTD determined in the Phase I portion.
After recovery from surgery (14-28 days), the patient will proceed to the efficacy component
of the trial.

After completion of study treatment, patients are followed up for 5 years.

Inclusion Criteria:

- Arm A Only: Subjects must have histologically confirmed World Health Organization
(WHO) grade III-IV newly diagnosed IDH1/2-mutant glioma.

- Arm B Only: WHO grades I-IV recurrent IDH1/2 mutant glioma. Subjects in Arm B must
have magnetic resonance imaging (MRI) confirming progressive disease; re-biopsy is
encouraged, but not required at the time of recurrence for confirmation.

- Patients with a primary spinal tumor, secondary glioma, or multifocal disease in the
brain, but without evidence of diffuse leptomeningeal spread, are eligible. In cases
where there are questions about multifocality versus diffuse leptomeningeal spread,
the study chair or co-chair must be contacted to make a final decision on eligibility.

- Subjects must have IDH1 or IDH2 mutation associated with neomorphic activity of the
encoded proteins.

- Subjects must be willing to provide archival formalin-fixed embedded (FFPE) and frozen
tissue specimens for biomarker studies if available.

- Subjects in Arm A must have been treated with maximal safe resection of primary tumor
followed by adjuvant radiation therapy (RT). Treatment with TMZ during radiation is
allowed but not required.

- Subjects in Arm B must have been treated with maximal safe resection of tumor.

- Lower grade glioma (LGG) subjects who progressed after initial surgery alone are
eligible. Any number of prior therapies are allowed.

- High grade glioma (HGG) subjects enrolled on Arm B must have been treated with a
minimum of maximal safe resection of primary tumor followed by adjuvant RT prior
to recurrence. Any number of prior therapies are allowed.

- Subjects must have fully recovered from the acute toxic effects of all prior
chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

- Myelosuppressive chemotherapy: subjects must have received their last dose of known
myelosuppressive anticancer chemotherapy at least three weeks prior to study
registration or at least six weeks if nitrosourea.

- Biologic agent: subjects must have recovered from any toxicity related to biologic
agents and received their last dose >= 7 days prior to study registration.

- For agents that have known adverse events occurring beyond 7 days after
administration, this period must be extended beyond the time during which adverse
events are known to occur. The duration of this interval should be discussed with
the study chair.

- For biologic agents that have a prolonged half-life, the appropriate interval
since last treatment should be discussed with the study chair prior to
registration.

- Monoclonal antibody treatment: at least three half-lives must have elapsed prior to
registration, and subjects on bevacizumab must have received their last dose >= 32
days prior to study registration.

- Subjects in Arm A should begin therapy with TMZ and BGB-290 after completion of
radiation therapy and when all other eligibility criteria are met.

- For subjects in Arm B, patients must not have received radiation therapy within 4
weeks prior to the initiation of study treatment. Post-RT, the diagnosis of true
progression versus ?pseudo-progression? can be challenging when imaging modalities are
exclusively used, and thus an additional resection is encouraged if clinically
indicated.

- Peripheral absolute neutrophil count (ANC) >= 1000/mm^3.

- Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving
platelet transfusions for at least 7 days prior to enrollment).

- Hemoglobin >= 9 g/dL.

- Serum creatinine =< 1.5 x upper limit of normal (ULN) or estimated creatinine
clearance >= 50 mL/min (calculated using the institutional standard method).

- Total serum bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of
normal (ULN).

- Aspartate and alanine aminotransferase (AST and ALT) =< 3 x ULN.

- Serum albumin >= 2 g/dL.

- Subjects with seizure disorder may be enrolled if on non-enzyme inducing
anticonvulsants and well controlled.

- Subjects who have neurological deficits should have deficits that are stable for a
minimum of 1 week prior to registration.

- Corticosteroids: Subjects who are receiving dexamethasone must be on a stable or
decreasing dose for at least 1 week prior to registration.

- The effects of BGB-290 on the developing human fetus are unknown. For this reason and
because alkylating agents (such as TMZ) are known to be teratogenic, women of
child-bearing potential and men must agree to use adequate contraception (hormonal or
barrier method of birth control; abstinence) prior to study entry, for the duration of
study participation and 4 months after completion of BGB-290 or TMZ administration.
Should a woman become pregnant or suspect she is pregnant while she or her partner is
participating in this study, she should inform her treating physician immediately.

- Subjects must be able to swallow capsules.

- Subjects must have the ability to undergo serial MRI scans (computerized tomography
[CT] cannot substitute for MRI).

- A legal parent/guardian or patient must be able to understand, and willing to sign, a
written informed consent and assent document, as appropriate.

- Karnofsky >= 50 for subjects > 16 years of age and Lansky >= 50 for subjects =< 16
years of age. Subjects who are unable to walk because of paralysis, but who are up in
a wheelchair, will be considered ambulatory for the purpose of assessing the
performance score.

Exclusion Criteria:

- Subjects who are receiving any other investigational agents and/or subjects previously
treated with small molecule inhibitors of mutant IDH1 or IDH2 proteins at any time may
not be enrolled.

- Subjects who have received a PARP inhibitor previously.

- Subjects with active infection requiring antibiotics at time of therapy start.

- Subjects with other diagnosis of malignancy.

- Subjects with clinically significant active bleeding disorder, hemoptysis, or melena
=< 6 months prior to day 1.

- Subjects on therapeutic anti-coagulation with heparin, warfarin, or other
anticoagulants:

- Use of low-dose aspirin and/or non-steroidal anti-inflammatory agents are
allowed.

- Use of thrombolytic to establish patency of indwelling venous catheters is
allowed.

- Prophylactic anticoagulation for venous access devices is allowed as long as
institutional normalized ratio (INR) is =< 1.5 and partial thromboplastin time
(aPTT) =< 1.5 x institutional ULN.

- Use of low-molecular weight heparin is allowed.

- Subjects with known disseminated leptomeningeal disease.

- Subjects with diffuse intrinsic pontine glioma (DIPG) are not eligible for this study.

- Unresolved acute effects of any prior therapy of grade >= 2, except for adverse events
(AEs) not constituting a safety risk by investigator judgement.

- Use =< 10 days (or =< 5 half-lives, whichever is shorter) prior to day 1 or
anticipated need for food or drugs known to be strong or moderate Cytochrome P450,
family 3, subfamily A (CYP3A) inhibitors or strong CYP3A inducers.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to TMZ or BGB-290.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Female subjects of childbearing potential must not be pregnant or breast-feeding.
Female subjects of childbearing potential must have a negative serum or urine
pregnancy test within 7 days of first dose.

- Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral
therapy are ineligible because of the potential for pharmacokinetic interactions with
BGB-290 and TMZ. In addition, these subjects are at increased risk of lethal
infections when treated with marrow-suppressive therapy.

- Subjects with inability to return for follow-up visits or obtain follow-up studies
required to assess toxicity to therapy.
We found this trial at
21
sites
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Karen M. Gauvain
Phone: 314-286-2790
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
700 Childrens Drive
Columbus, Ohio 43205
(616) 722-2000
Principal Investigator: Mohamed S. AbdelBaki
Phone: 614-722-4087
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
?
mi
from
Columbus, OH
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Principal Investigator: Ashley S. Margol
Phone: 323-361-8147
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Amar Gajjar
Phone: 901-595-2615
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
747 52nd St
Oakland, California 94609
(510) 428-3000
Principal Investigator: Tabitha M. Cooney
Phone: 510-428-3885
Children's Hospital and Research Center Oakland For nearly 100 years, Children's Hospital & Research Center...
?
mi
from
Oakland, CA
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Principal Investigator: Jane E. Minturn
Phone: 267-426-5026
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Kellie J. Nazemi
Phone: 614-722-4087
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
3020 Childrens way
San Diego, California 92123
(858) 576-1700
Principal Investigator: John R. Crawford
Phone: 858-966-4939
Rady Children's Hospital - San Diego Rady Children's Hospital-San Diego is the region’s pediatric medical...
?
mi
from
San Diego, CA
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Kenneth J. Cohen
Phone: 410-614-5055
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Susan N. Chi
Phone: 617-632-2291
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Charlestown, Massachusetts 02129
Principal Investigator: David H. Ebb
Phone: 617-726-2737
?
mi
from
Charlestown, MA
Click here to add this to my saved trials
Chicago, Illinois 60614
Principal Investigator: Stewart Goldman
Phone: 312-227-4873
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1600 Southwest Archer Road
Gainesville, Florida 32610
Principal Investigator: Sridharan Gururangan
Phone: 352-294-8347
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
6621 Fannin St
Houston, Texas 77030
(832) 824-1000
Principal Investigator: Patricia A. Baxter
Texas Children's Hospital Texas Children's Hospital, located in Houston, Texas, is a not-for-profit organization whose...
?
mi
from
Houston, TX
Click here to add this to my saved trials
2450 Riverside Avenue
Minneapolis, Minnesota 55454
Principal Investigator: Christopher L. Moertel
Phone: 612-626-2778
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: Asher M. Marks
Phone: 203-785-4640
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
2000 Circle of Hope Dr
Salt Lake City, Utah 84112
(801) 585-0303
Principal Investigator: Nicholas S. Whipple
Phone: 801-662-4700
Huntsman Cancer Institute at University of Utah Huntsman Cancer Institute (HCI) is part of the...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Sabine Mueller
Phone: 415-502-1600
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
4800 Sand Point Way NE
Seattle, Washington 98105
(206) 987-2000
Principal Investigator: Sarah E. Leary
Phone: 206-667-7995
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
555 University Avenue
Toronto, Ontario M5G 1X8
Principal Investigator: Eric Bouffet
Phone: 416-813-7360
?
mi
from
Toronto,
Click here to add this to my saved trials
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Principal Investigator: Lindsay B. Kilburn
Phone: 202-476-5973
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials